Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug
Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.
You may also be interested in...
North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.
Company plans to meet with caregivers and consider other options before moving forward.
Desmopressin's limited efficacy over placebo doesn't dissuade FDA's advisory committee, which votes 14 to 4 in favor of approval even as many suggest indication be narrowed.